Ildong Holdings Co., Ltd. (000230.KS) Stock

000230.KS logo

Ildong Holdings Co., Ltd.

000230.KSSouth Korea
Healthcare

Company profile

Ildong Holdings reported revenue of 590.89 billion KRW for fiscal year 2025, down 10.1% from fiscal year 2024, and net income of 10.93 billion KRW. That is a net profit margin of 1.8% for fiscal year 2025. Its largest business segment, Medicines Manufacturing and Sales, brought in 88% of segment revenue in fiscal year 2024; South Korea was the largest region with 97%. Our analysis of its filings shows revenue shrinking from 638.45 billion KRW in fiscal year 2023 to 590.89 billion KRW in fiscal year 2025, 3.8% a year on average. Ildong Holdings reports about 136 full-time employees.

What stands out

  • Net income fell 82.7% in fiscal year 2025, from 63.04 billion KRW in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Ildong Holdings Co., Ltd.

Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online; and manufactures original and generic prescription drugs. Further, it offers probiotics; pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions; and engages in advertising business. The company was formerly known as Ildong Pharmaceutical Co., Ltd. and changed its name to Ildong Holdings Co., Ltd. in August 2016. Ildong Holdings Co., Ltd. was founded in 1941 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Woong-Sub Yoon18.14 %18.14%
  • Won-Young Yoon14.83 %14.83%
  • Songpa Foundation7.12%
  • Kyung-ja Lim6.175 %6.17%
  • Hye-jin Yoon0.1547 %0.15%

Share of the company, as of September 25, 2026

Leadership

  • Woongseop Yoon — CEO & Vice Chairman, 58
  • Wonyoung Yoon — President, 87
  • Yong-Sik Kang — Managing Director and Director, 65

How much revenue does Ildong Holdings make?

Ildong Holdings reported 590.89 billion KRW in revenue for fiscal year 2025, down 10.1% from 657.57 billion KRW in fiscal year 2024.

What is Ildong Holdings's largest business segment?

Medicines Manufacturing and Sales, with 614.94 billion KRW or 88% of segment revenue in fiscal year 2024. Next: Cosmetic Surgery Medical Devices Manufacturing, Sales and Software Development (4%) and Health Functionality Food (3%).

Where does Ildong Holdings make most of its revenue?

South Korea: 97% of revenue by region in fiscal year 2024, followed by Other (2%).

What companies are similar to Ildong Holdings?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Daehan Nupharm Co.,Ltd. (054670.KQ), PharmGen Science, Inc. (004720.KS), Ctcbio Inc. (060590.KQ), Icure Pharmaceutical Incorporation (175250.KQ).

Has Ildong Holdings made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 70.89 billion KRW; FY2022, a loss of 102.35 billion KRW; FY2023, a loss of 59.59 billion KRW; FY2024, 63.04 billion KRW; FY2025, 10.93 billion KRW. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees136
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
2, Baumoe-ro 27-gil, Seoul, 06752
Phone
82 2 526 3114
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Ildong Holdings Co., Ltd. (000230.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/000230.KS

LinkedInLinkedInXXYouTubeYouTube